Prevents rejection in renal homotransplantation. ANDA 77621, held by Zydus Pharms USA. Azathioprine.
As of Nov 16, 2026, ANDA 77621 (Azathioprine), held by Zydus Pharms USA, was first approved by FDA on Mar 15, 2007, with 6 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Azathioprine tablets, USP are indicated as an adjunct for the prevention of rejection in renal homotransplantation. It is also indicated for the management of active rheumatoid arthritis to reduce signs and symptoms. Renal Homotransplantation Azathioprine tablets, USP are
| Date | Submission | Status | Documents |
|---|---|---|---|
| Mar 15, 2007 | Original application | Approved | None posted |
| Azathioprine50MG · tablet;oral | Azathioprine | Rx |
| Azathioprine25MG · tablet;oral | Azathioprine | Rx |
| Azathioprine75MG · tablet;oral | Azathioprine | Rx |
| Azathioprine100MG · tablet;oral | Azathioprine | Rx |
| May 23, 2025 | Supplement 21Labeling · Standard review | Approved | None posted |
| Apr 23, 2019 | Supplement 13Labeling · Standard review | Approved | None posted |
| Jul 20, 2015 | Supplement 8Labeling · Standard review | Approved | None posted |
| Jun 20, 2011 | Supplement 5Labeling | Approved | None posted |
| Feb 17, 2009 | Supplement 4Labeling | Approved | None posted |
| Sep 5, 2008 | Supplement 2Labeling | Approved | None posted |
| Mar 15, 2007 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters